TY - JOUR
T1 - From Targets to Treatments
T2 - Bridging Autoimmune Research to Advance Understanding of Alopecia Areata
AU - Kranz, Dory
AU - Ellison, Abby
AU - Frelinger, Jeffrey A.
AU - Mackay-Wiggan, Julian
AU - Norris, David A.
N1 - Funding Information:
Funding for the Summit and the publication of this supplement was provided by the National Alopecia Areata Foundation and was made possible (in part) by R13AR067088-01 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and all co-funding support provided by the National Center for Advancing Translational Sciences. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US Government.
Funding Information:
JAF owns Amgen stock, received grant support from the NIH, and received royalties from the sale of monoclonal antibodies, paid through the University of Southern California. AE and DK received grant support from NIAMS, National Center for Advancing Translational Sciences, Rxi Pharmaceuticals, and Summer Labs. JM-W received grant support from Locks of Love and AA Initiative—Gates Foundation. DAN states no conflict of interest.
Publisher Copyright:
© 2015 The Society for Investigative Dermatology.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Alopecia areata is a common autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body that affects over 146 million people worldwide at some point in their lives. Founded in 1981, the National Alopecia Areata Foundation (NAAF) is a nonprofit organization that supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. NAAF conducts research summits every 2 years that are central to achieving the goals of a major strategic initiative, the Alopecia Areata Treatment Development Program, which are: to accelerate progress toward a safe, effective, affordable treatment or a cure for alopecia areata. These summits have played a key role in transforming the understanding of alopecia areata from largely inflammatory and dermatological perspectives to a focus on the genetic and immunological factors that are now recognized as driving and active determinants of the disease process.
AB - Alopecia areata is a common autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body that affects over 146 million people worldwide at some point in their lives. Founded in 1981, the National Alopecia Areata Foundation (NAAF) is a nonprofit organization that supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. NAAF conducts research summits every 2 years that are central to achieving the goals of a major strategic initiative, the Alopecia Areata Treatment Development Program, which are: to accelerate progress toward a safe, effective, affordable treatment or a cure for alopecia areata. These summits have played a key role in transforming the understanding of alopecia areata from largely inflammatory and dermatological perspectives to a focus on the genetic and immunological factors that are now recognized as driving and active determinants of the disease process.
UR - http://www.scopus.com/inward/record.url?scp=84946737478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946737478&partnerID=8YFLogxK
U2 - 10.1038/jidsymp.2015.29
DO - 10.1038/jidsymp.2015.29
M3 - Editorial
C2 - 26551934
AN - SCOPUS:84946737478
SN - 1087-0024
VL - 17
SP - 1
EP - 5
JO - Journal of Investigative Dermatology Symposium Proceedings
JF - Journal of Investigative Dermatology Symposium Proceedings
IS - 2
ER -